GlassScriptPhysician profile
Garth David Phibbs
NPI 1205817939
$1,774.46
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $890 · 2020: $563 · 2021: $321.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Clovis Oncology, INC. | $563.22 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $306.47 | 2019-2021 | |
| Glaxosmithkline, LLC. | $237.21 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $158.32 | 2019-2021 | |
| Eisai INC. | $82.36 | 2019-2020 | |
| Therapeuticsmd, INC. | $77.11 | 2019-2021 | |
| Amgen INC. | $72.38 | 2019 | |
| Genentech USA, INC. | $67.47 | 2019 | |
| Astellas Pharma US INC | $59.19 | 2019-2021 | |
| Kyowa Kirin, INC. | $48.67 | 2019 | |
| Daiichi Sankyo INC. | $23.75 | 2021 | |
| Biom'Up Sa | $18.06 | 2019 | |
| Fortovia Therapeutics, INC. | $16.93 | 2019 | |
| Mallinckrodt Enterprises LLC | $15.61 | 2019 | |
| Covidien LP | $14.45 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acelrx Pharmaceuticals, INC. | $13.26 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Garth Phibbs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.